Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insys Therapeutics, Inc.INSY · Entity 156931 | Director | April 02, 2018 | April 23, 2019 |
| Surrozen, Inc./DESRZN · Entity 6092 | Chief Medical Officer | December 15, 2022 | December 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insys Therapeutics, Inc.
Report date April 02, 2018 · Filed April 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,083 |
Ending reported balance
After 2019-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-02 · Grant · Acquired 6,000 · Balance 6,000 Row 2 · 2019-03-04 · Grant · Acquired 8,083 · Balance 14,083 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2028-04-01 | Direct | 24,000 |
Reported balance
After 2018-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-02 · Grant · Acquired 24,000 · Balance 24,000 F1: The option vests in 36 equal monthly installments and will be fully vested and exercisable on April 2, 2021. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-03-03 | Direct | 20,935 |
Reported balance
After 2019-03-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-04 · Grant · Acquired 20,935 · Balance 20,935 F2: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 36 equal monthly installments and will be fully vested and exercisable on April 2, 2021.
F2: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022.
Surrozen, Inc./DE
Report date December 15, 2022 · Filed December 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,412 |
Reported balance
After 2022-12-15 transaction · row 1
1 source rowRow 1 · 2022-12-15 · Grant · Acquired 9,578 · Balance 32,412 F1: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2022 Filed Dec 19, 2022 18:53 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantCommon Stock | 9,578 | $0.41 | $3,926.98 |
DisclosureSEC source: 0001593968-22-001746 · primary_01.xml · nonDerivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,412 F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,760 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 8 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,760 Underlying: Common Stock · 1,760 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to her on 2/23/2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 24,587 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 7 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,587 Underlying: Common Stock · 24,587 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to her on 2/23/2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 10,427 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 6 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,427 Underlying: Common Stock · 10,427 shares Expires 2031-08-12 F3 · price: The reporting person agreed to cancellation of an option granted to her on 8/12/2021, in exchange for a new option having a lower exercise price. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 26,220 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 5 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,220 Underlying: Common Stock · 26,220 shares Expires 2031-08-12 F3 · price: The reporting person agreed to cancellation of an option granted to her on 8/12/2021, in exchange for a new option having a lower exercise price. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 1,760 | Not disclosed Strike: $10.77 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 4 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,760 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to her on 2/23/2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 26,220 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 3 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,220 shares Expires 2031-08-12 F3 · price: The reporting person agreed to cancellation of an option granted to her on 8/12/2021, in exchange for a new option having a lower exercise price. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 10,427 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 2 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,427 shares Expires 2031-08-12 F3 · price: The reporting person agreed to cancellation of an option granted to her on 8/12/2021, in exchange for a new option having a lower exercise price. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 24,587 | Not disclosed Strike: $10.77 | Not disclosed |
DisclosureSEC source: 0001593968-22-001522 · primary_01.xml · derivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,587 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to her on 2/23/2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 20:54 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption Grant (right to buy) · Derivative | 125,000 | $3.11 Strike: $3.11 | $388,750.00 |
DisclosureSEC source: 0001593968-22-000636 · primary_01.xml · derivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2022, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:07 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantEmployee Stock Option (right to buy) · Derivative | 36,647 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0001209191-21-051723 · doc4.xml · derivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,647 Underlying: Common Stock · 36,647 shares Expires 2031-08-11 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| March 04, 2019 Filed Apr 19, 2019 21:30 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 20,935 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001209191-19-025408 · doc4.xml · derivative · entry 4 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 Underlying: Common Stock · 20,935 shares Expires 2029-03-03 F2 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. Read SEC document |
| March 04, 2019 Filed Apr 19, 2019 21:30 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025408 · doc4.xml · nonDerivative · entry 2 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 Read SEC document |
| March 04, 2019 Filed Apr 23, 2019 19:14 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 20,935 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001209191-19-025631 · doc4.xml · derivative · entry 4 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 Underlying: Common Stock · 20,935 shares Expires 2029-03-03 F2 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. Read SEC document |
| March 04, 2019 Filed Apr 23, 2019 19:14 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025631 · doc4.xml · nonDerivative · entry 2 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 Read SEC document |
| April 02, 2018 Filed Apr 19, 2019 21:30 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001209191-19-025408 · doc4.xml · derivative · entry 3 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-04-01 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on April 2, 2021. Read SEC document |
| April 02, 2018 Filed Apr 19, 2019 21:30 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025408 · doc4.xml · nonDerivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| April 02, 2018 Filed Apr 23, 2019 19:14 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001209191-19-025631 · doc4.xml · derivative · entry 3 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-04-01 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on April 2, 2021. Read SEC document |
| April 02, 2018 Filed Apr 23, 2019 19:14 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025631 · doc4.xml · nonDerivative · entry 1 Vanhove Geertrui · CIK 0001771994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.